Reports Q2 revenue $82.5M, consensus $80.99M. “Our strong second quarter keeps us firmly on track to achieve no less than $320 million in ORLADEYO revenue this year, as our base of patients grows larger and larger every quarter. While ORLADEYO revenues continue to grow, we are also excited to host an R&D day in November to introduce new molecules and programs from our discovery platform that have the potential to replicate or exceed the success of ORLADEYO,” said Jon Stonehouse, president and chief executive officer of BioCryst.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BCRX:
- BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
- Is BCRX a Buy, Before Earnings?
- BioCryst to Report Second Quarter 2023 Financial Results on August 3
- BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey
- BioCryst selects Er-Kim as commercial partner for ORLADEYO in Turkey